Introduction to invention patents
Application of Fusarium brevicaulis in the production of mycelial protein

Fushine Pharmaceuticals recently received an invention patent from the State Intellectual Property Office for "The Application of Fusarium brevicaulis in the Production of Mycelial Proteins." This patent marks a significant step forward for Fushine Pharmaceuticals in the field of synthetic biology, injecting a breath of fresh, green energy into the food industry.
According to "Low-Carbon Biomanufacturing of Future Foods" published in the Journal of Biotechnology (2022, 38[11]: 4311-4328), Fusarium is a filamentous fungus that is widely used for fermentation to produce microbial protein. The mycelial protein it produces is more delicious than single-cell proteins such as yeast and bacteria, and has a meat-like tissue structure. At the same time, the rich edible crude fiber it contains helps human gastrointestinal digestion, making it a meat substitute that can meet the nutritional needs of modern people.

Patent prospects
The State Council issued opinions on practicing the big food concept and building a diversified food supply

In recent years, the concept of "Big Food" has been frequently mentioned, quietly leading a revolution in our dining table. With technological innovation, the boundaries of food are infinitely broadened. This "Big Food" concept advocates the comprehensive and multi-faceted development of food resources. This extends beyond traditional grains, fruits, and vegetables to encompass microbial fermentation and even novel foods created through synthetic biology.

Leveraging its years of experience in the pharmaceutical industry, the company has expanded its synthetic biology microbial protein business and has become the first domestic company to achieve ton-scale industrialization of filamentous fungal protein. The company has developed a novel production strain, Fusarium brevicaulis, with complete intellectual property rights. The China Light Industry Federation's Appraisal Committee has certified the project's "Key Technologies and Industrial Applications for Fermentation Production of Microbial Protein with Fusarium brevicaulis" as having reached internationally advanced technology levels. The committee also unanimously approved the project's approval and recommended increased promotion and application efforts.

While enjoying the strong endorsement provided by the national macro-policies, Fushine Pharmaceuticals has successfully obtained the invention patent for "Application of Fusarium brevis in the production of mycelial protein" through unremitting efforts. This not only marks that Fushine Pharmaceuticals' intensive cultivation in the field of biotechnology has yielded fruitful results, but also consolidates and expands Fushine Pharmaceuticals' leading position in the industry, forms an intellectual property advantage, and helps Fushine Pharmaceuticals gain a favorable position in the global market competition, promoting the company to achieve sustainable development and industry leadership.

Fushine Pharmaceuticals is currently transforming its research findings into productive capabilities, bringing microbial protein products to the homes of ordinary people. Fushine is also actively collaborating with upstream and downstream companies, increasing R&D investment, and exploring new technologies and applications in the field of microbial protein. We look forward to the vigorous development of the microbial protein industry, which will undoubtedly set off a new trend of "green, healthy, and efficient" products in the global market.